Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Update

Century Therapeutics, Inc. (NASDAQ:IPSC) was the target of a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 3,391,589 shares, a growth of 320.2% from the January 15th total of 807,117 shares. Approximately 4.1% of the company’s stock are sold short. Based on an average daily trading volume, of 1,809,997 shares, the days-to-cover ratio is presently 1.9 days. Based on an average daily trading volume, of 1,809,997 shares, the days-to-cover ratio is presently 1.9 days. Approximately 4.1% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on IPSC shares. Zacks Research raised Century Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 6th. Leerink Partners cut Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 17th. Piper Sandler raised their target price on shares of Century Therapeutics from $2.00 to $4.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Finally, Wall Street Zen cut shares of Century Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, February 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Century Therapeutics has an average rating of “Moderate Buy” and an average price target of $3.80.

Insider Buying and Selling at Century Therapeutics

In related news, CEO Brent Pfeiffenberger acquired 52,000 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was bought at an average price of $0.58 per share, for a total transaction of $30,160.00. Following the completion of the purchase, the chief executive officer directly owned 3,322,990 shares of the company’s stock, valued at approximately $1,927,334.20. The trade was a 1.59% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Chad Cowan acquired 58,060 shares of the company’s stock in a transaction on Monday, December 22nd. The shares were purchased at an average cost of $0.85 per share, for a total transaction of $49,351.00. Following the acquisition, the insider owned 1,045,087 shares of the company’s stock, valued at approximately $888,323.95. The trade was a 5.88% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders bought 145,060 shares of company stock valued at $97,011 and sold 66,018 shares valued at $30,213. Corporate insiders own 4.37% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its position in shares of Century Therapeutics by 109.1% during the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock valued at $67,000 after acquiring an additional 34,466 shares during the period. AQR Capital Management LLC raised its holdings in Century Therapeutics by 358.9% during the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock worth $53,000 after purchasing an additional 86,875 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Century Therapeutics by 26.9% during the first quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock worth $86,000 after purchasing an additional 38,052 shares during the last quarter. Acadian Asset Management LLC boosted its position in Century Therapeutics by 101.2% during the first quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock worth $133,000 after purchasing an additional 142,953 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Century Therapeutics in the second quarter valued at $50,000. 50.20% of the stock is owned by hedge funds and other institutional investors.

Century Therapeutics Trading Down 2.2%

Shares of Century Therapeutics stock traded down $0.04 during trading hours on Thursday, hitting $1.75. 1,021,893 shares of the company were exchanged, compared to its average volume of 1,510,654. Century Therapeutics has a 1 year low of $0.34 and a 1 year high of $2.71. The business has a 50-day moving average of $1.46 and a 200-day moving average of $0.86. The stock has a market capitalization of $152.95 million, a price-to-earnings ratio of -5.47 and a beta of 1.75.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. As a group, research analysts anticipate that Century Therapeutics will post -1.61 earnings per share for the current fiscal year.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.